Alta Fox Capital Management added 776,975 shares in BrightSpring Health Services; the estimated trade value was $26.06 million based on quarterly average prices.
Meanwhile, the quarter-end position value increased by $32.73 million, reflecting both share purchase and price movement.
The post-trade stake totaled 1,237,500 shares valued at $46.34 million as of December 31, 2025.
BrightSpring stake now 9.97% of fund AUM.
On February 13, 2026, Alta Fox Capital Management disclosed a buy of 776,975 shares of BrightSpring Health Services (NASDAQ:BTSG) in the fourth quarter, an estimated $26.06 million trade based on quarterly average pricing.
According to its SEC filing dated February 13, 2026, Alta Fox Capital Management increased its position in BrightSpring Health Services (NASDAQ:BTSG) by 776,975 shares during the fourth quarter. The estimated transaction value was approximately $26.06 million, calculated using the average share price over the quarter. At quarter-end, the stake’s value had risen by $32.73 million, reflecting both the purchase and stock price appreciation.
| Metric | Value |
|---|---|
| Revenue (TTM) | $13.3 billion |
| Net income (TTM) | $110.3 million |
| Market capitalization | $7.01 billion |
| Price (as of market close February 12, 2026) | $37.79 |
BrightSpring Health Services, Inc. is a leading provider of home and community-based healthcare services in the United States, with a significant scale and a diversified service offering. The company leverages its integrated platform to deliver both pharmacy and direct care services to a broad patient base, primarily serving Medicare, Medicaid, and insured populations. BrightSpring's strategy centers on expanding access to care in non-institutional settings, positioning the company to benefit from long-term trends in healthcare delivery and population health management.
Healthcare is shifting steadily away from institutions and into the home, and that secular trend is not slowing down. That backdrop makes a near 10% portfolio allocation to BrightSpring notable, especially as the company scales both pharmacy and provider services in tandem.
In the third quarter, BrightSpring generated $3.33 billion in revenue, up 28% year over year, with adjusted EBITDA climbing 37% to $160 million. Net income from continuing operations swung to $37.5 million from a loss a year earlier, and management also raised full year revenue guidance to as much as $12.8 billion and expects adjusted EBITDA between $605 million and $615 million, implying more than 30% growth.
Within the portfolio, the position now sits alongside other concentrated bets, but healthcare services offers a different risk profile than cyclical or tech holdings. Ultimately, if BrightSpring continues converting top line growth into durable cash flow while navigating reimbursement risk, the current run may prove to be more than just the finish line.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CarGurus. The Motley Fool has a disclosure policy.